Literature DB >> 28576185

Brachytherapy in the Management of Prostate Cancer.

Bradley J Stish1, Brian J Davis2, Lance A Mynderse3, Christopher L Deufel2, Richard Choo2.   

Abstract

Brachytherapy is performed by directly inserting radioactive sources into the prostate gland and is an important treatment option for appropriately selected men with prostate adenocarcinoma. Brachytherapy provides highly conformal radiotherapy and delivers tumoricidal doses that exceed those administered with external beam radiation therapy. There is a significant body of literature supporting the excellent long-term oncologic and safety outcomes achieved when brachytherapy is used for men in all risk categories of nonmetastatic prostate cancer. This article highlights some important considerations and published outcomes that relate to brachytherapy and its role in the treatment of prostate cancer.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dose escalation; High dose rate brachytherapy; Image guidance; Low dose rate brachytherapy; Prostate cancer; Radiation therapy

Mesh：

Year:  2017        PMID： 28576185     DOI： 10.1016/j.soc.2017.01.008

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN： 1055-3207            Impact factor:   3.495


  6 in total

Review 1.  A single institution analysis of low-dose-rate brachytherapy: 5-year reported survival and late toxicity outcomes.

Authors:  Michael Chao; Sandra Spencer; Mario Guerrieri; Wei Ding; Mehran Goharian; Huong Ho; Michael Ng; Danielle Healey; Alwin Tan; Chee Cham; Daryl Lim Joon; Nathan Lawrentschuk; Douglas Travis; Shomik Sengupta; Yee Chan; Andrew Troy; Trung Pham; David Clarke; Peter Liodakis; Damien Bolton
Journal:  J Contemp Brachytherapy       Date:  2018-04-30

2.  Predicting pubic arch interference in permanent prostate brachytherapy based on the specific parameters derived from nuclear magnetic resonance imaging.

Authors:  Yupeng Zheng; Jixiang Wu; Shan Chen; Yuexin Liu; Guangyin Zhang
Journal:  J Contemp Brachytherapy       Date:  2018-10-25

3.  Improving rectal dosimetry for patients with intermediate and high-risk prostate cancer undergoing combined high-dose-rate brachytherapy and external beam radiotherapy with hydrogel space.

Authors:  Michael Chao; Darren Ow; Huong Ho; Yee Chan; Daryl Lim Joon; Sandra Spencer; Nathan Lawrentschuk; Mario Guerrieri; Trung Pham; Kevin McMillan; Alwin Tan; Farshad Foroudi; Johann Tang; Jason Wasiak; Madalena Liu; George Koufogiannis; Chee Wee Cham; Damien Bolton
Journal:  J Contemp Brachytherapy       Date:  2019-02-28

4.  Prostate Cancer Survivors Present Long-Term, Residual Systemic Immune Alterations.

Authors:  Katalin Balázs; Zsuzsa S Kocsis; Péter Ágoston; Kliton Jorgo; László Gesztesi; Gyöngyi Farkas; Gábor Székely; Zoltán Takácsi-Nagy; Csaba Polgár; Géza Sáfrány; Zsolt Jurányi; Katalin Lumniczky
Journal:  Cancers (Basel)       Date:  2022-06-22       Impact factor: 6.575

5.  Impact of Statin Use on Localized Prostate Cancer Outcomes after Radiation Therapy: Long-Term Follow-Up.

Authors:  Kevin Kaulanjan; Danny Lavigne; Fred Saad; Pierre I Karakiewicz; Rocco Simone Flammia; Luis Alex Kluth; Philipp Mandel; Felix K-H Chun; Daniel Taussky; Benedikt Hoeh
Journal:  Cancers (Basel)       Date:  2022-07-24       Impact factor: 6.575

Review 6.  Bone Health Management in the Continuum of Prostate Cancer Disease.

Authors:  Ettickan Boopathi; Ruth Birbe; Sunday A Shoyele; Robert B Den; Chellappagounder Thangavel
Journal:  Cancers (Basel)       Date:  2022-09-02       Impact factor: 6.575
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.